Atsunori Kashiwagi

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 15

Top Topics

Acute Heart Failure

Top Venues

Journal of diabetes investigation

Endocrine journal

This page only lists publications with an associated author ORCID identifier.

Publications

Masaki Kobayashi, Nobuhiro Maruyama, Yukako Yamamoto, Takeshi Togawa, Takanori Ida, Morikatsu Yoshida, Mikiya Miyazato, Masahisa Kitada, Yoshitaka Hayashi, Atsunori Kashiwagi, Tadahiro Kitamura
A newly developed glucagon sandwich ELISA is useful for more accurate glucagon evaluation than the currently used sandwich ELISA in subjects with elevated plasma proglucagon-derived peptide levels. Journal of diabetes investigation (2023)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Yoko Yoshinaga, Mitsuhiro Rokuda
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis. Journal of diabetes investigation 15 (3) (2023)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Yoko Yoshinaga, Mitsuhiro Rokuda
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis. Journal of diabetes investigation 15 (3) (2023)
Yukako Yamamoto, Takeshi Togawa, Osamu Sekine, Yuki Ozamoto, Junko Fuse, Choka Azuma, Jun Ito-Kobayashi, Yasumitsu Oe, Akeo Hagiwara, Masaki Kobayashi, Tadahiro Kitamura, Masanori Iwanishi, Akira Shimatsu, Atsunori Kashiwagi
The oral disposition index calculated from a meal tolerance test is a crucial indicator for evaluating differential normalization of postprandial glucose and triglyceride excursions in morbidly obese patients after laparoscopic sleeve gastrectomy. Endocrine journal (2023)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Yoko Yoshinaga, Mitsuhiro Rokuda
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis. Journal of diabetes investigation 15 (3) (2023)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Yoko Yoshinaga, Mitsuhiro Rokuda
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis. Journal of diabetes investigation 15 (3) (2023)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Yoko Yoshinaga, Mitsuhiro Rokuda
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis. Journal of diabetes investigation (2023)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Tadashi Koga, Keiko Asakawa, Mitsuhiro Rokuda
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan. Journal of diabetes investigation 14 (3) (2022)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Tadashi Koga, Keiko Asakawa, Mitsuhiro Rokuda
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan. Journal of diabetes investigation 14 (3) (2022)
Atsunori Kashiwagi, Shingo Shoji, Satoshi Onozawa, Yoshinori Kosakai, Miina Waratani, Yuichiro Ito
Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in Japan. Journal of diabetes investigation 13 (7) (2022)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Tadashi Koga, Keiko Asakawa, Mitsuhiro Rokuda
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan. Journal of diabetes investigation (2022)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Tadashi Koga, Keiko Asakawa, Mitsuhiro Rokuda
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan. Journal of diabetes investigation 14 (3) (2022)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Tadashi Koga, Keiko Asakawa, Mitsuhiro Rokuda
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan. Journal of diabetes investigation 14 (3) (2022)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Tadashi Koga, Keiko Asakawa, Mitsuhiro Rokuda
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan. Journal of diabetes investigation 14 (3) (2022)
Atsunori Kashiwagi, Shin-Ichi Araki, Hiroshi Maegawa
Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients. Journal of diabetes investigation 12 (1) (2020)